Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
VERTEX PHARMACEUTICALS INC / MA
Bear Case (25th pct.)
-64.8% vs price
Base Case (Median)
-41.1% vs price
Bull Case (75th pct.)
-31.1% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $433.11 | -18.1% | High (40%) |
| PE Comparable | $390.28 | -26.2% | Medium (25%) |
| Growth Trajectory DCF | $338.31 | -36.0% | Medium (20%) |
| Graham Number | $168.59 | -68.1% | Medium (40%) |
| EV/EBITDA | $203.83 | -61.5% | Medium (20%) |
| EV/FCF | $311.28 | -41.1% | Medium (20%) |
| Earnings Power Value | $162.20 | -69.3% | Medium (50%) |
Based on 7 out of 7 methods, VRTX appears overvalued at the current price of $528.83. The base case fair value of $311.28 implies 41.1% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.